Taysha Gene Therapies, Inc. (TSHA)
TSHA chart
Everything the smart money is doing in TSHA
This is the TSHA details page members see in the GTA Terminal. Previews below are blurred samples; start a free trial to see the live data.
Option Flows for TSHA
Every unusual options bet in TSHA: size, strikes, expirations and which side the money is on.
Start 14-day free trialAlready a member? Open in the Terminal →Insiders & Congress for TSHA
1 insider filings on record for TSHA. See who bought and sold, how much, and when.
Start 14-day free trialAlready a member? Open in the Terminal →Institutions for TSHA
Which hedge funds and institutions are buying and selling TSHA.
Start 14-day free trialAlready a member? Open in the Terminal →Short interest for TSHA
Short interest data for TSHA through 2026-09-30: percent of shares short, days to cover and the squeeze score.
Start 14-day free trialAlready a member? Open in the Terminal →Financials & earnings for TSHA
Eight quarters of revenue, margins and EPS for TSHA, every earnings beat and miss, and conference-call notes.
Start 14-day free trialAlready a member? Open in the Terminal →GTA AI for TSHA
Ask GTA AI for a trade idea on TSHA: bias, entry, stop and target, built from all of the data above.
Start 14-day free trialAlready a member? Open in the Terminal →Sample previews with placeholder values. Then $99/month. Cancel anytime.
Technical summary daily
| Moving average | Simple | Exponential | Signal |
|---|---|---|---|
| MA5 | 4.25 | 4.17 | Sell |
| MA10 | 4.44 | 4.38 | Sell |
| MA20 | 4.71 | 4.66 | Sell |
| MA50 | 5.43 | 5.16 | Sell |
| MA100 | 5.69 | 5.41 | Sell |
| MA200 | 5.41 | 5.29 | Sell |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 21.16 | Oversold |
| MACD(12,26) | -0.35 | Sell |
| Stochastic(14) | 1.15 | Oversold |
| ROC(12) | -19.38 | Sell |
Classic pivot points from the last full session. Technical signals are mechanical readings, not recommendations.
Taysha Gene Therapies, Inc. news
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book ValueSimply Wall St. · Oct 9, 2026Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?Simply Wall St. · Oct 9, 2026How do you see Taysha Gene Therapies, Inc. today?
Results show once a few readers have voted today.
Historical data daily, last 20 sessions
| Date | Price | Open | High | Low | Vol. | Change % |
|---|---|---|---|---|---|---|
| Oct 13, 2026 | 3.77 | 4.09 | 4.13 | 3.75 | 1.63M | -9.06% |
| Oct 12, 2026 | 4.14 | 4.46 | 4.56 | 4.12 | 4.21M | -7.80% |
| Oct 09, 2026 | 4.49 | 4.42 | 4.57 | 4.36 | 5.38M | +1.35% |
| Oct 08, 2026 | 4.43 | 4.37 | 4.45 | 4.32 | 3.91M | 0.00% |
| Oct 07, 2026 | 4.43 | 4.33 | 4.46 | 4.26 | 3.91M | +0.91% |
| Oct 06, 2026 | 4.39 | 4.51 | 4.57 | 4.26 | 4.83M | -2.23% |
| Oct 05, 2026 | 4.49 | 4.64 | 4.64 | 4.37 | 4.97M | -3.02% |
| Oct 02, 2026 | 4.63 | 4.80 | 4.86 | 4.63 | 2.99M | -2.32% |
| Oct 01, 2026 | 4.74 | 4.86 | 4.93 | 4.73 | 3.85M | -2.67% |
| Sep 30, 2026 | 4.87 | 5.03 | 5.03 | 4.82 | 3.90M | -2.40% |
| Sep 29, 2026 | 4.99 | 4.97 | 5.03 | 4.80 | 6.57M | 0.00% |
| Sep 28, 2026 | 4.99 | 4.64 | 5.05 | 4.56 | 6.26M | +6.85% |
| Sep 25, 2026 | 4.67 | 4.88 | 4.88 | 4.66 | 4.66M | -2.51% |
| Sep 24, 2026 | 4.79 | 4.88 | 4.90 | 4.66 | 6.40M | -2.44% |
| Sep 23, 2026 | 4.91 | 5.11 | 5.14 | 4.88 | 5.51M | -4.84% |
| Sep 22, 2026 | 5.16 | 5.11 | 5.22 | 5.08 | 2.31M | +2.38% |
| Sep 21, 2026 | 5.04 | 5.07 | 5.12 | 4.99 | 1.68M | +0.40% |
| Sep 18, 2026 | 5.02 | 5.16 | 5.28 | 4.96 | 9.12M | -2.71% |
| Sep 17, 2026 | 5.16 | 5.25 | 5.46 | 5.05 | 4.08M | +1.78% |
| Sep 16, 2026 | 5.07 | 5.08 | 5.14 | 4.97 | 4.35M | +0.20% |
Full history, intraday charts and downloads are in the GTA Terminal.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
People also watch
FAQ
What is the price of Taysha Gene Therapies, Inc. today?
Taysha Gene Therapies, Inc. (TSHA) last traded at 3.77, down 9.06% on the day.
What is the 52-week range of TSHA?
Over the past 52 weeks TSHA has traded between 3.69 and 7.30.
Is TSHA a buy or a sell?
Daily technical indicators currently read Strong Sell (0 buy vs 8 sell signals). That is a mechanical reading, not advice.
Get the GTA Daily Brief
The market's biggest stories each morning, plus what options traders, insiders and Congress are doing with their money. Free.